中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
Chinese Journal of Experimental Surgery
2015年
10期
2481-2484
,共4页
周建良%朱志刚%丁静丽%徐建军%杨威%龚艺
週建良%硃誌剛%丁靜麗%徐建軍%楊威%龔藝
주건량%주지강%정정려%서건군%양위%공예
聚乙二醇%血管内皮生长因子%迈克尔加成反应%去细胞瓣%支架
聚乙二醇%血管內皮生長因子%邁剋爾加成反應%去細胞瓣%支架
취을이순%혈관내피생장인자%매극이가성반응%거세포판%지가
Polyethylene glycol%Vascular endothelial growth factor%Michael addition reaction%Decellularized valve%Scaffold
目的 基于迈克尔加成反应,体外构建经血管内皮生长因子(VEGF)共价修饰的去细胞猪主动脉瓣(DPAV)复合材料,探讨复合瓣膜的力学性能和生物学性能.方法 应用枝状化聚乙二醇(PEG)对去细胞的猪主动脉瓣PEG化,PEG化去细胞瓣(PEG-DPAV)与VEGF上的巯基发生反应,将VEGF共价修饰到去细胞瓣上(VEGF-PEG-DPAV).检测VEGF共价修饰去细胞瓣的效果;对复合瓣膜在周向和径向上力学性能进行测试;通过差示扫描量热仪(DSC)、溶血实验和细胞毒性实验测试复合瓣膜的生物学性能.结果 通过红外光谱和免疫荧光检测证实VEGF成功共价修饰到去细胞瓣上,苏木素-伊红(HE)染色和扫描电镜显示去细胞瓣膜交联PEG后,纤维增粗、排列整齐,结构更加致密.力学性能测试显示去细胞瓣PEG化后可以改善部分力学性能.DSC显示DPAV、PEG-DPAV和VEGF-PEG-DPAV组瓣膜的变性温度分别为(65.64 ±0.15)℃、(74.94±0.10)℃和(74.88 ±0.05)℃.溶血实验显示DPAV、PEG-DPAV和VEGF-PEG-DPAV组溶血率分别为(0.23±0.01)％、(0.24±0.01)％和(0.23±0.01)％.DPAV、PEG-DPAV和VEGF-PEG-DPAV组瓣膜均未表现出细胞毒性.结论 成功制备经VEGF修饰的PEG化去细胞瓣,为体外去细胞瓣的改性研究提供一种可行性方法.
目的 基于邁剋爾加成反應,體外構建經血管內皮生長因子(VEGF)共價脩飾的去細胞豬主動脈瓣(DPAV)複閤材料,探討複閤瓣膜的力學性能和生物學性能.方法 應用枝狀化聚乙二醇(PEG)對去細胞的豬主動脈瓣PEG化,PEG化去細胞瓣(PEG-DPAV)與VEGF上的巰基髮生反應,將VEGF共價脩飾到去細胞瓣上(VEGF-PEG-DPAV).檢測VEGF共價脩飾去細胞瓣的效果;對複閤瓣膜在週嚮和徑嚮上力學性能進行測試;通過差示掃描量熱儀(DSC)、溶血實驗和細胞毒性實驗測試複閤瓣膜的生物學性能.結果 通過紅外光譜和免疫熒光檢測證實VEGF成功共價脩飾到去細胞瓣上,囌木素-伊紅(HE)染色和掃描電鏡顯示去細胞瓣膜交聯PEG後,纖維增粗、排列整齊,結構更加緻密.力學性能測試顯示去細胞瓣PEG化後可以改善部分力學性能.DSC顯示DPAV、PEG-DPAV和VEGF-PEG-DPAV組瓣膜的變性溫度分彆為(65.64 ±0.15)℃、(74.94±0.10)℃和(74.88 ±0.05)℃.溶血實驗顯示DPAV、PEG-DPAV和VEGF-PEG-DPAV組溶血率分彆為(0.23±0.01)％、(0.24±0.01)％和(0.23±0.01)％.DPAV、PEG-DPAV和VEGF-PEG-DPAV組瓣膜均未錶現齣細胞毒性.結論 成功製備經VEGF脩飾的PEG化去細胞瓣,為體外去細胞瓣的改性研究提供一種可行性方法.
목적 기우매극이가성반응,체외구건경혈관내피생장인자(VEGF)공개수식적거세포저주동맥판(DPAV)복합재료,탐토복합판막적역학성능화생물학성능.방법 응용지상화취을이순(PEG)대거세포적저주동맥판PEG화,PEG화거세포판(PEG-DPAV)여VEGF상적구기발생반응,장VEGF공개수식도거세포판상(VEGF-PEG-DPAV).검측VEGF공개수식거세포판적효과;대복합판막재주향화경향상역학성능진행측시;통과차시소묘량열의(DSC)、용혈실험화세포독성실험측시복합판막적생물학성능.결과 통과홍외광보화면역형광검측증실VEGF성공공개수식도거세포판상,소목소-이홍(HE)염색화소묘전경현시거세포판막교련PEG후,섬유증조、배렬정제,결구경가치밀.역학성능측시현시거세포판PEG화후가이개선부분역학성능.DSC현시DPAV、PEG-DPAV화VEGF-PEG-DPAV조판막적변성온도분별위(65.64 ±0.15)℃、(74.94±0.10)℃화(74.88 ±0.05)℃.용혈실험현시DPAV、PEG-DPAV화VEGF-PEG-DPAV조용혈솔분별위(0.23±0.01)％、(0.24±0.01)％화(0.23±0.01)％.DPAV、PEG-DPAV화VEGF-PEG-DPAV조판막균미표현출세포독성.결론 성공제비경VEGF수식적PEG화거세포판,위체외거세포판적개성연구제공일충가행성방법.
Objective We established decellularized valvemodified by vasculaendothelial growth facto(VEGF) in vitro based on michael addition reaction, and explored theimechanical and biological properties.Method4-arm-polyethylene glycol (PEG)-acrylate waused to PEGylate the decellularized aortivalves.The PEGylated decellularized valvewere modified by VEGF in vitro.The establishmenresulof composite valvewaobserved.Mechanical propertieof valvewere tested acircumferential and radial directions.Theibiological propertiewere measured by DSC, hemolytiand cytotoxicity test.ResultWe confirmed thaPEGylated decellularized valvewere successfully modified by VEGF viFourietransform infrared spectroscopy and immunofluorescence.The decellularized resultshowed collagen fiberthickened in alignment.MechanicPerformance Testing showed thaPEGylated valvecould improve parmechanical properties.DSdisplayed denaturation temperatureof DPAV, PEG-DPAV and VEGF-PEG-DPAV were (65.64 ± 0.15) ℃, (74.94 ± 0.10) ℃ and (74.88 ± 0.05) ℃ respectively.Hemolytitesshowed hemolysiratiowere (0.23 ±0.01)％, (0.24 ± 0.01)％ and (0.23 ± 0.01) ％ , respectively.No cytotoxicity waobserved in DPAV, PEG-DPAV and VEGF-PEG-DPAV.Conclusion We successfully established PEGylated decellularized valvemodified by VEGF, which provided feasible method in scaffold modification of decellularized valvein vitro.
